ny reported sales, Productview Plus includes data for 1,100 ethical drugs from over 110 companies and across 147 product classes. Productview Plus provides five years of historical sales as well as a seven-year forecast for all drugs, split by United States and Rest of World regions -- allowing users to get a universal understanding of a company's/drug's current and future position.
Productview Plus is available now from Decision Resources.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources
781-296-2563
emarshall@dresources.com
'/>"/>SOURCE Decision Resources Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Actuaries: Addressing Health Spending Growth is Path to Sustainable Health Care System2.
Covance To Present at Bairds 2009 Growth Stock Conference3.
Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results4.
Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine5.
AMN Healthcare Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference and at the Robert W. Baird 2009 Growth Stock Conference6.
Adolescent Growth Plate Injuries May Be Related to Overuse7.
Despite the Economic Downturn, Long-Term Growth Potential in the US Dental Biomaterial Market Remains Robust8.
Process controlling T cell growth and production identified9.
Injured Marines at Risk for Abnormal Bone Growth10.
Injured Marines at risk for abnormal bone growth11.
Genoptix Reports Strong Growth for the First Quarter of 2009